Masakazu Toi

44.6k total citations · 7 hit papers
666 papers, 21.5k citations indexed

About

Masakazu Toi is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Masakazu Toi has authored 666 papers receiving a total of 21.5k indexed citations (citations by other indexed papers that have themselves been cited), including 399 papers in Oncology, 266 papers in Cancer Research and 177 papers in Molecular Biology. Recurrent topics in Masakazu Toi's work include Breast Cancer Treatment Studies (177 papers), HER2/EGFR in Cancer Research (149 papers) and Cancer Treatment and Pharmacology (139 papers). Masakazu Toi is often cited by papers focused on Breast Cancer Treatment Studies (177 papers), HER2/EGFR in Cancer Research (149 papers) and Cancer Treatment and Pharmacology (139 papers). Masakazu Toi collaborates with scholars based in Japan, United States and Germany. Masakazu Toi's co-authors include Hiroko Bando, Chikashi Nakanishi, Takeshi Tominaga, Takayuki Ueno, Katsumasa Kuroi, Shigehira Saji, Martin Frenzel, Susana Barriga, Norikazu Masuda and Joohyuk Sohn and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Masakazu Toi

644 papers receiving 21.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs

2005 642 citations Masakazu Toi et al. profile →
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

1996 631 citations Masakazu Toi et al. profile →
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.

2000 617 citations Takayuki Ueno, Masakazu Toi et al. profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations George W. Sledge, Masakazu Toi et al. profile →
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

2019 407 citations Stephen Johnston, Miguel Martín et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masakazu Toi Japan	68	10.8k	8.0k	6.9k	6.1k	2.2k	666	21.5k
Naoto T. Ueno United States	72	11.0k 1.0×	5.6k 0.7×	6.5k 0.9×	3.7k 0.6×	2.0k 0.9×	547	20.4k
John Crown Ireland	71	13.0k 1.2×	7.4k 0.9×	6.0k 0.9×	4.8k 0.8×	2.4k 1.0×	416	20.1k
Hiroji Iwata Japan	63	16.7k 1.5×	4.8k 0.6×	7.1k 1.0×	9.6k 1.6×	1.9k 0.8×	520	23.8k
David S. Hong United States	77	10.4k 1.0×	9.5k 1.2×	5.8k 0.8×	6.3k 1.0×	1.3k 0.6×	817	23.2k
Giampaolo Tortora Italy	69	13.8k 1.3×	9.9k 1.2×	4.8k 0.7×	7.8k 1.3×	1.9k 0.8×	639	24.4k
Mario Campone France	66	15.3k 1.4×	7.6k 1.0×	7.1k 1.0×	9.0k 1.5×	3.2k 1.4×	538	23.9k
Timothy A. Chan United States	77	10.4k 1.0×	9.4k 1.2×	5.2k 0.7×	5.5k 0.9×	1.4k 0.6×	243	22.7k
Bryan T. Hennessy Ireland	59	9.0k 0.8×	9.7k 1.2×	6.4k 0.9×	3.0k 0.5×	1.6k 0.7×	266	19.8k
Patricia LoRusso United States	69	11.2k 1.0×	10.9k 1.4×	2.8k 0.4×	4.4k 0.7×	2.2k 1.0×	569	21.9k
Manuel Hidalgo United States	85	18.5k 1.7×	12.5k 1.6×	7.4k 1.1×	7.0k 1.2×	1.2k 0.5×	448	29.7k

Countries citing papers authored by Masakazu Toi

Since Specialization

Citations

This map shows the geographic impact of Masakazu Toi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masakazu Toi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masakazu Toi more than expected).

Fields of papers citing papers by Masakazu Toi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masakazu Toi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masakazu Toi. The network helps show where Masakazu Toi may publish in the future.

Co-authorship network of co-authors of Masakazu Toi

This figure shows the co-authorship network connecting the top 25 collaborators of Masakazu Toi. A scholar is included among the top collaborators of Masakazu Toi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masakazu Toi. Masakazu Toi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolaney, Sara M., Zefei Jiang, Qingyuan Zhang, et al.. (2025). Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 394(6). 551–562. 2 indexed citations

Tokunaga, Eriko, Hiroji Iwata, Tatsuya Toyama, et al.. (2024). Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast Cancer. 32(1). 132–143. 2 indexed citations

Takano, Toshimi, Norikazu Masuda, Mitsuya Ito, et al.. (2024). Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Research and Treatment. 207(1). 33–48. 2 indexed citations

Kataoka, Masako, Mami Iima, Maya Honda, et al.. (2023). Evaluation of breast lesions based on modified BI-RADS using high-resolution readout-segmented diffusion-weighted echo-planar imaging and T2/T1-weighted image. Magnetic Resonance Imaging. 98. 132–139. 4 indexed citations

Toi, Masakazu, Frances Boyle, Young‐Hyuck Im, et al.. (2022). Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1. The Oncologist. 28(1). e77–e81. 12 indexed citations

Goetz, Matthew P., Miguel Martín, Eriko Tokunaga, et al.. (2020). Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer. The Oncologist. 25(9). e1346–e1354. 35 indexed citations

Yamashiro, Hiroyasu, Hiroji Iwata, Norikazu Masuda, et al.. (2020). Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer. 27(4). 631–641. 5 indexed citations

Perez, Edith A., Carlos H. Barrios, W. Eiermann, et al.. (2019). Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE. Cancer. 125(22). 3974–3984. 79 indexed citations

Sugie, Tomoharu, Eiji Suzuki, Akira Yamauchi, et al.. (2018). Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. The Breast. 38. 114–119. 9 indexed citations

10.

Takada, Masahiro, Masahiro Sugimoto, Norikazu Masuda, et al.. (2018). Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Research and Treatment. 172(3). 611–618. 18 indexed citations

11.

Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology. 35(25). 2875–2884. 1103 indexed citations breakdown →

12.

André, Fabrice, Sara A. Hurvitz, Angelica Fasolo, et al.. (2016). Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology. 34(18). 2115–2124. 135 indexed citations

13.

Chow, Louis WC, Stewart Y. Tung, Seock‐Ah Im, et al.. (2013). Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II – III invasive breast cancer: the OOTR-N001 study. Expert Opinion on Investigational Drugs. 22(3). 299–307. 17 indexed citations

14.

Imami, Koshi, Naoyuki Sugiyama, Masaki Wakabayashi, et al.. (2012). Temporal Profiling of Lapatinib-suppressed Phosphorylation Signals in EGFR/HER2 Pathways. Molecular & Cellular Proteomics. 11(12). 1741–1757. 38 indexed citations

15.

Kondo, Masahide, et al.. (2012). Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Research and Treatment. 133(2). 759–768. 20 indexed citations

16.

Toi, Masakazu, Hiroji Iwata, Yasuhiro Fujiwara, et al.. (2009). Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. British Journal of Cancer. 101(10). 1676–1682. 68 indexed citations

17.

Suzuki, Eiji, Rinpei Niwa, Shigehira Saji, et al.. (2007). A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients. Clinical Cancer Research. 13(6). 1875–1882. 91 indexed citations

18.

Toi, Masakazu, et al.. (2005). Trastuzumab: updates and future issues. Cancer Chemotherapy and Pharmacology. 56(S1). 94–99. 17 indexed citations

19.

Kanzaki, Atsuko, Masakazu Toi, Nouri Neamati, et al.. (2002). Copper‐transporting P‐Type Adenosine Triphosphatase (ATP7B) Is Expressed in Human Breast Carcinoma. Japanese Journal of Cancer Research. 93(1). 70–77. 43 indexed citations

20.

Osaki, Akihiko, et al.. (1992). Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. The American Journal of Surgery. 164(4). 323–326. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact